Table 2. . Rho kinase inhibitors.

No.	Structure	Inhibitor class	Publication year	Activity
13		HTS compound	2008	IC50 = 7.2 nM
14		Synthetic ‘isoquinoline prototype’	1997	Ki = 330 nM
15		Fasudil derivative approved for glaucoma treatment in Japan	2014	ROCK-I (IC50 = 51 nM); ROCK-II (IC50 = 19 nM)
16		Synthetic ‘isoquinoline series’	1997	Ki = 1.6 nM
17		Synthetic ‘4-aminopyridine series’	1997	Ki = 0.14 µM
18		Synthetic ‘pyrrolopyridine series’	2007	ROCK-II (IC50 = 3.6 nM)
19		Synthetic ‘indazole series’	2006	IC50 = 13 nM
20		Synthetic benzadioxane-based compound	2008	ROCK-I (IC50 = 56 nM)
21		Tetrahydroisoquinoline-based inhibitor	2010	ROCK-II (IC50 <1 nM)
22		Selective ROCK-II inhibitor	2011	ROCK-II (IC50 = 1.7 nM)
23		Tricyclic pyridocarboxamide derivatives	2015	ROCK-II (IC50 = 1 nM)
24		Structure-based drug design inhibitor	2014	IC50 = 1.5 μM
25		Structure-based design inhibitor	2013	ROCK-II (IC50 = 0.02 μM)
26		Ligand-based drug design inhibitor	2011	ROCK-II (IC50 = 0.02 μM)

HTS: High-throughput screening; ROCK: Rho kinase.